Table 1.

Use of EBRT in definitive management of primary penile squamous cell carcinoma.

Study	Pts, n	RT dose, Gy	Median follow-up, month	5-year LC, %	5-year CSS, %	5-year penile preservation, %	Stenosis or necrosis rate	Tumor characteristic	Tumor location
McLean et al., 1993 [22]	26	35 Gy/10 fx; 60 Gy/25 fx	116	61	69	66	•NR (seven Pts with late complications)	•73.1% T1; 15.3% T2; 7.7% T3; 3.9% T4	•65% glans or prepuce; 4% shaft; 31% multiple sites
Sarin et al., 1997 [29]	59	60 Gy/30 fx	62	55	66	50	•3% necrosis; 14% stenosis	•86.4% T1; 8.5% T2; 1.7% T3; 3.4% T4	•In 101 Pts, 78% were confined to glans; only 59 received EBRT
Gotsadze et al., 2000 [25]	155	40–60 Gy	40	65	86	65	•1% necrosis; 7% stenosis	•36.8% T1; 55.5% T2; 7.7% T3;	•NR
Zouhair et al., 2001 [27]	23	45–74 Gy/25–37 fx	12	41	NR	36	•10% stenosis	•29% T1; 59% T2; 10% T3; 2% Tx	•In 41 Pts: 41% glans; 22% prepuce; 20% shaft; 10% corona; 5% prepuce or glans; 2% prepuce or shaft
Azrif et al., 2006 [24]	41	50.0–52.5 Gy/16 fx	41	62	96	62	•8% necrosis; 29% stenosis	•90.2% T1; 9.8% T2	•98% glans/prepuce
Ozsahin et al., 2006 [23]	21	52 Gy	62	49	NR	52	•10% stenosis	•37% T1; 53% T2; 8% T3; 2% Tx	•In 60 Pts: 40% glans; 26% prepuce; 22% shaft; 7% corona; 3% prepuce/glans; 1% prepuce/shaft
Mistry et al., 2007 [26]	18	55 Gy/16 fx−50 Gy/20fx	62	63	NR	62	• 10% necrosis; 5% stenosis	•23.5% Tx; 17.6% in situ; 35.3% T1; 17.6% T2; 6% T3	•In 65 Pts: 76% were on glans/prepuce; 5% on shaft

CSS, cancer-specific survival; EBRT, external beam radiotherapy; Pts, patients; RT, radiotherapy; LC, local control; NR, not reported.